Immunome gains 34% after preclinical data on COVID-19 antibody

Jun. 30, 2022 2:41 PM ETImmunome, Inc. (IMNM)By: Dulan Lokuwithana, SA News Editor

Antibodies attacking SARS-CoV-2 virus

Dr_Microbe/iStock via Getty Images

  • Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday after data indicated that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern, including BA.1 and BA.2.
  • IMM-BCP-01 consists of three patient-derived neutralizing antibodies that target non-overlapping regions on the SARS-CoV-2 spike protein.
  • According to results published in the journal Science Immunology, IMM-BCP-01 was found to have decreased Omicron infection in the lungs of Syrian golden hamsters.
  • The lab results have also indicated potential antiviral effector response, including phagocytosis, antibody-mediated cellular cytotoxicity and complement pathway activation.
  • Citing their findings, the researchers wrote: “…IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals.”

  • Early this month, Immunome (IMNM) announced the dosing initiation of an early-stage study for IMM-BCP-01 involving recently diagnosed COVID-19 patients. The topline data from the single dose, dose escalation study is expected in 2H 2022.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.